Skip to main content

Lymphaticovenous Anastomosis (LVA / LVB)

Lymphaticovenous anastomosis (LVA) — also termed lymphovenous bypass (LVB) or lymphaticovenular anastomosis — is the physiologic microsurgical procedure that creates direct bypasses between functional lymphatic collectors and subdermal venules, channeling lymph into the venous system. In genital lymphedema it accounts for 14.5% of all GL surgeries and carries the lowest complication rate (9%) of any approach — comparable to primary closure (10%) and dramatically lower than excision + flap (54.2%).[1]

For the clinical condition see Genital Lymphedema; for the conservative anchor see Complex Decongestive Therapy; for excisional alternatives see Debulking Scrotoplasty and the Modified Charles Procedure.

Mechanism​

LVA creates surgical bypasses between functional collecting lymphatics and adjacent subdermal venules, redirecting lymph into the venous system. Unlike excisional debulking, LVA is physiologic — it restores drainage capacity. The fundamental prerequisite is the presence of functional lymphatic vessels; sclerosed lymphatics require VLNT instead.[2]

Indications​

General​

  • Compression-refractory lymphedema after ≥ 6 mo of CDT.[3]
  • Functional / patent lymphatic vessels on preoperative imaging.[2][4]
  • ISL Stage I–III — traditionally early-stage; modern imaging (multi-lymphosome ICG, lymphatic ultrasound, "milestone-swirl" approach) has expanded LVA into advanced Stage III with functional vessels found in 83.3% of limbs.[5][6][7]
  • Grade 1C evidence (AAPS consensus).[3]

Genital-specific​

  • Secondary GL after pelvic lymphadenectomy (prostate, bladder, gynecologic cancers) — the most common urologic indication.[8]
  • Primary GL with severe lymphorrhea — simultaneous multi-site LVA at lower-extremity and genital sites.[9]
  • Genital acquired lymphangiectasia (GAL) — LVA + GAL resection reduces recurrence (33.3% with type-1 lymphatic flow vs 75% without).[10][11]
  • Moderate inguinal-node dysfunction with hyperplasia on MR lymphography (Lu algorithm).[12]

Preoperative Imaging​

ModalityRole
ICG lymphographyMost widely used; staged by dermal-backflow pattern — linear → splash → stardust → diffuse. Multi-lymphosome ICG injection identifies more vessels and shortens OR time.[13][15]
MR lymphangiography (MRL)Deeper anatomic detail; coincident MRL + ICG yields functional-vessel detection in 96.9% and successful LVA in 91.4%; contrast-enhanced MRL adds 12% more vessels at 99% localization accuracy.[16][17]
Lymphatic ultrasoundDetects more vessels than ICG (mean 1.9 vs 0.6 per area, p < 0.05) — expands LVA eligibility in advanced disease.[6]
CEUS with microbubblesWhen ICG fails or is unavailable — 100% vessel identification; 58% of anastomoses mapped by CEUS only.[18]
LymphoscintigraphyGold standard for diagnosis but poor spatial resolution; staging severity / LyTI.[19]

NECST Classification — intraoperative vessel grading​

TypeDescriptionICG correlationLVA suitability
N (Normal)Normal-caliber, healthyLinearExcellent
E (Ectasis)Dilated, wall intactLinear / SplashOptimal — 81.2% of successful LVA sites
C (Contraction)Narrowed, thickened, reduced lumenStardustFeasible — comparable 1-yr volume reduction to non-contraction types
S (Sclerosis)Fibrotic, obliteratedDiffusePoor — highest failure; avoid D-region on ICG

Ectasis-type vessels are the ideal targets. Risk factors for severe sclerosis (s3) — higher BMI, thigh / foot incision (vs groin), diffuse dermal backflow.[20][21][22][28][29]

Surgical Technique​

General principles. Minimally invasive outpatient procedure under local anesthesia through 2-cm incisions; supermicrosurgical microscope (25–50×); 11-0 / 12-0 nylon; vessels typically 0.3–0.8 mm.[4][9][30]

Six-step method (Rodriguez & Yamamoto)[4]​

  1. Preop mapping — ICG ± MRL ± ultrasound; mark sites where lymphatics and veins are in close proximity.
  2. Incision and dissection — 2-cm incisions; isolate lymphatic vessels and subdermal venules.
  3. Vessel assessment — NECST type; confirm functional flow on transection. Prefer ectasis.
  4. Recipient vein selection — only 31% of veins are reflux-free; prefer reflux-free veins to prevent venous backflow into the lymphatic.
  5. Anastomosis — 11-0 / 12-0 nylon under supermicrosurgical magnification.
  6. Patency confirmation — intraoperative ICG or patent blue dye.

Anastomotic configurations​

ConfigurationBest forKey advantage
End-to-end (EEA)Size-matched vesselsSimplest; most common (50.3%)
End-to-side (ESA)LV ≫ RV size discrepancyAccommodates mismatch (45.6%)
Side-to-end (SEA)Bidirectional lymph captureGreatest efficacy in advanced disease (significantly better volume reduction in ISL II late / III); needs only one anastomosis per LV

The SEATTLE procedure (Side-to-End Anastomosis Through Temporary Lymphatic Expansion) facilitates SEA via temporary dilation — 95.5% success; SEA is not recommended for LV diameter ≤ 0.35 mm.[30][31][32][33][34]

Number of anastomoses​

Average 3.1–7.1 per patient; median OR time 27.2 min per LVA. Multi-lymphosome ICG increases anastomoses (5.06 vs 4.21, p = 0.001) and improves outcomes.[4][15][30]

Genital-Specific LVA Techniques​

TechniqueDetail
Spermatic-cord LVA (Mukenge)Anastomose lymphatic collectors of the spermatic funiculus to veins of the pampiniform plexus — captures testicular lymphatic drainage missed by superficial scrotal LVA. n = 5 secondary GL after PLND — patency confirmed at 3, 6, 12 mo; soft scrotum, normochromic skin, no pain, edema resolution, normal testicular palpability.[8]
Simultaneous multi-site LVA (Yamamoto)Lower-extremity + genital sites in primary LE with severe lymphorrhea; 2-cm incisions, 2–3 microscopes, local anesthesia; clinical improvement in both edema and lymphorrhea.[9]
LVA for genital acquired lymphangiectasia (Hara & Mihara)Lower-limb LVA + GAL resection reduces recurrence. Patients with type 1 lymphatic flow (leg-to-genital communication on lymphoscintigraphy) — recurrence 33.3% vs 75% in those without isotope accumulation.[10][11]

Outcomes​

PopulationVolume reductionFollow-upSeries
UEL (supermicro LVA)Median 67% (7–93%)33 moRodriguez & Yamamoto n = 229[4]
LEL (supermicro LVA)Median 41% (7–81%)33 moRodriguez & Yamamoto n = 229[4]
UEL prospective meta-analysis14.26% mean reduction at 1 yr21.8 moBrown n = 431[36]
UEL all-studies pooled~29% improvementVariableHahn meta-analysis[37]
LEL advanced stage83.3% with circumference reductionVariableHara & Mihara[5]
Genital secondaryComplete edema resolution12 moMukenge n = 5[8]
LVA + CDT vs CDT alone–6.21% vs +3.23% (p < 0.0001)12 moZeltzer n = 92[35]

Cellulitis reduction​

  • 4.22 → 0.10 episodes / 2 yr (p < 0.001) — Thomas n = 150[38]
  • 2.1 → 0.2 episodes / yr[4]
  • Pooled meta-analysis — UEL −1.13 episodes/yr, LEL −1.32 episodes/yr.[39]
  • Genital LE — cellulitis frequency reduced in all patients.[10]

Compression and QoL​

  • 46.3% reduced or discontinued compression therapy (meta-analysis); 65% UEL / 40% LEL discontinued garments; significant decreases in days/week and hours/day at 24 mo (p < 0.001).[36][38][40]
  • EQ-5D-5L p < 0.001; Lymph-ICF 43.9 → 30.6 (p < 0.001); LLIS improved 7.0 → 27.5 points from 3 mo → 3 yr.[38][40][41]

Cost-effectiveness​

LVA reduced mean 24-mo cellulitis-related costs by £1,389.85 per patient; ICER £54,231 / QALY (including £4,551 surgery cost); benefits extend beyond the 24-mo capture window.[42]

Patency and Long-Term Durability​

  • 76% of patients show ≥ 1 patent anastomosis at 12 mo (ICG).[43]
  • 56.5% of individual anastomoses remain patent at 12 mo.[44]
  • Cumulative patency 75% / 36% at 12 / 24 mo (SEA).[45]
  • Long-term patency of multiple LVAs confirmed by lymphoscintigraphy at 5 yr; LyTI normalized.[46]

Hemodynamic critique. Kang 2026 — in upright posture (16–18 hr/day) ankle venous pressure rises to 80–100 mmHg while lymphatic pressure rises modestly, creating a reversal that may impair lower-extremity LVA function; clinical improvement sometimes persists despite declining patency, suggesting concurrent conservative therapy / selection bias may contribute.[47]

Complications​

  • Overall complication rate — 9% in GL (Guiotto SR); 12.9% in combined LVA + VLNT extremity series.[1][48]
  • No complications in the LVA group in a head-to-head LVA-vs-VLNT lower-limb comparison.[49]
  • No flap loss (no flap involved).
  • Wound complications minimal — small 2-cm incisions heal readily.
  • Anastomotic thrombosis / occlusion — primary concern; mitigated by reflux-free vein selection and SEA with distal vein ligation.[4][33][34]

Prophylactic LVA (LYMPHA)​

SeriesSettingResult
Boccardo 2026 (15-yr follow-up, n = 500)Breast cancer + RTLymphedema 2.5% LYMPHA + RT vs 45% non-LYMPHA + RT (cumulative LE-free probability 0.978 vs 0.587, p < 0.001).[50]
Hinson meta-analysis (17 studies)MixedImmediate LVA → RR 0.31 (95% CI 0.23–0.42, p < 0.001) — 69% lower risk.[51]
Ozmen S-LYMPHASimplified techniqueLymphedema 19% → 3% (OR 0.12, p = 0.001); feasible without microsurgical expertise.[52]
Cho 9-yr pLVB n = 370BreastBCRL 8.7% with pLVB vs 20.1% without (p < 0.001).[53]

Urologic relevance. The principle is directly applicable to pelvic lymphadenectomy for prostate / bladder / penile cancers — a major cause of secondary genital lymphedema, underutilized in urologic oncology.[8]

LVA vs VLNT​

FeatureLVAVLNT
MechanismBypass lymph into venous systemTransplant functional lymph nodes
PrerequisiteFunctional lymphatic vesselsNo functional lymphatics needed
Best stageEarly-to-moderate (expanding into advanced)Moderate-to-advanced
InvasivenessMinimally invasive; local; outpatientMajor; general; donor-site morbidity
Volume reduction (UEL pooled)~29%~42%
Cellulitis reduction (UEL)−1.13 / yr−2.43 / yr
OnsetRapid (within 3 mo)Gradual (over 12+ mo)
ComplicationsVery low (0% in some series)Low but higher than LVA
ConsensusGrade 1CGrade 1B

Simultaneous LVA + VLNT — 21.4% volume reduction at 1 yr; 36.2% at 2 yr.[3][36][37][39][41][48][49][56]

LVA Within the GL Treatment Algorithm​

SeverityMRL findingRecommended approach
MildMild inguinal-node dysfunctionCDT alone
Moderate (hyperplasia)Moderate dysfunction + hyperplasiaLVA ± CDT
Moderate-severe (hypoplasia)Moderate-severe + hypoplasiaSurgical excision ± VLNT
Advanced / elephantiasisSevere dysfunctionExcision + SCIP-lymphatic flap transfer
[12][57]

LVA is the first-line surgical option for patients failing CDT who still have functional lymphatic vessels; it can be combined with excisional or VLNT approaches for more advanced disease.[1][2][56][58]

Key Urologic Takeaways​

  1. LVA has the lowest complication rate (9%) of any GL surgical approach and is the only one that restores physiologic lymphatic drainage.[1]
  2. Spermatic-cord LVA (funiculus lymphatics → pampiniform plexus veins) addresses testicular lymphatic drainage missed by superficial scrotal LVA.[8]
  3. Preoperative imaging is essential — ICG, MRL, and lymphatic ultrasound are complementary; ultrasound detects more vessels than ICG in advanced disease.[6]
  4. Side-to-end configuration delivers superior volume reduction in advanced disease.[32]
  5. Prophylactic LVA (LYMPHA) at PLND could dramatically reduce secondary GL — well-established in breast cancer / axillary surgery, underutilized in urologic oncology.[50][51]
  6. LVA combines effectively with excisional procedures or VLNT for advanced GL.[1][56]

See Also​

References​

1. Guiotto M, Bramhall RJ, Campisi C, Raffoul W, di Summa PG. A systematic review of outcomes after genital lymphedema surgery. Ann Plast Surg. 2019;83(6):e85–e91. doi:10.1097/SAP.0000000000001875

2. Haas Y, Williams OP, Masia J, et al. Microsurgical vs complex physical decongestive therapy for chronic BCRL. Cochrane Database Syst Rev. 2025;2:CD016019. doi:10.1002/14651858.CD016019

3. Chang DW, Dayan J, Greene AK, et al. Surgical treatment of lymphedema: systematic review and meta-analysis. Plast Reconstr Surg. 2021;147(4):975–993. doi:10.1097/PRS.0000000000007783

4. Rodriguez JR, Yamamoto T. A systematic stepwise method to perform a supermicrosurgical lymphovenous anastomosis. Ann Plast Surg. 2022;88(5):524–532. doi:10.1097/SAP.0000000000003023

5. Hara H, Mihara M. Lymphaticovenous anastomosis for advanced-stage lower-limb lymphedema. Microsurgery. 2021;41(2):140–145. doi:10.1002/micr.30689

6. Hara H, Mihara M. Lymphatic ultrasound detects more vessels than ICG lymphography in lymphedematous limbs. J Plast Reconstr Aesthet Surg. 2025;113:85–91. doi:10.1016/j.bjps.2025.11.005

7. Yoshimatsu H, Cho MJ, Inoue K, et al. Combining ICG lymphography and ultrasonography to identify lymphatic vessels in advanced-stage lymphedema — the milestone-and-swirl-sign approach. J Plast Reconstr Aesthet Surg. 2025;102:134–141. doi:10.1016/j.bjps.2025.01.016

8. Mukenge SM, Catena M, Negrini D, et al. Assessment and follow-up of patency after lymphovenous microsurgery for secondary lymphedema in external male genital organs. Eur Urol. 2011;60(5):1114–1119. doi:10.1016/j.eururo.2010.11.020

9. Yamamoto T, Koshima I, Yoshimatsu H, et al. Simultaneous multi-site LVA for primary lower-extremity and genital lymphoedema with severe lymphorrhea. J Plast Reconstr Aesthet Surg. 2011;64(6):812–815. doi:10.1016/j.bjps.2010.10.011

10. Hara H, Mihara M. LVA and resection for genital acquired lymphangiectasia (GAL). J Plast Reconstr Aesthet Surg. 2018;71(11):1625–1630. doi:10.1016/j.bjps.2018.05.015

11. Hara H, Mihara M. Genital LVA and leg LVA to prevent recurrence of GAL. Microsurgery. 2021;41(5):412–420. doi:10.1002/micr.30733

12. Lu Q, Jiang Z, Zhao Z, et al. MR lymphography for male genital lymphedema. Medicine (Baltimore). 2016;95(21):e3755. doi:10.1097/MD.0000000000003755

13. Yamamoto T, Narushima M, Doi K, et al. Characteristic ICG lymphography findings in lower-extremity lymphedema — novel staging using DB patterns. Plast Reconstr Surg. 2011;127(5):1979–1986. doi:10.1097/PRS.0b013e31820cf5df

15. Xia L, Wang Y, Wang W, et al. Influence of multipoint ICG injections on LVA-surgery outcome in lower-limb lymphedema. Ann Vasc Surg. 2025;118:98–103. doi:10.1016/j.avsg.2025.04.065

16. Pons G, Clavero JA, Alomar X, et al. Preoperative planning of LVA — MRL as a complement to ICG lymphography. J Plast Reconstr Aesthet Surg. 2019;72(6):884–891. doi:10.1016/j.bjps.2019.02.024

17. Zhu J, Guo Q, Huang Y, et al. Clinical value of contrast-enhanced MR lymphatic vessel imaging for precise localization in LVA. J Plast Reconstr Aesthet Surg. 2025;105:385–394. doi:10.1016/j.bjps.2025.04.017

18. Jang S, Lee CU, Hesley GK, et al. Lymphatic mapping using US microbubbles before LVA surgery for lymphedema. Radiology. 2022;304(1):218–224. doi:10.1148/radiol.212351

19. Kadle RL, Chao AH. Imaging modalities in lymphatic surgery. Expert Rev Med Devices. 2025. doi:10.1080/17434440.2025.2554760

20. Mihara M, Hara H, Kawakami Y. Ultrasonography for classifying lymphatic sclerosis types and deciding optimal LVA sites. J Plast Reconstr Aesthet Surg. 2018;71(9):1274–1281. doi:10.1016/j.bjps.2018.05.012

21. Yamamoto T, Yamamoto N, Yoshimatsu H, Narushima M, Koshima I. Factors associated with lymphosclerosis — 962 lymphatic vessels. Plast Reconstr Surg. 2017;140(4):734–741. doi:10.1097/PRS.0000000000003690

22. Hara H, Mihara M, Seki Y, et al. ICG findings vs collecting-lymphatic-vessel condition in lymphedema. Plast Reconstr Surg. 2013;132(6):1612–1618. doi:10.1097/PRS.0b013e3182a97edc

28. Hara H, Mihara M. LVA map established using lymphatic ultrasound and multi-lymphosome ICG. J Plast Reconstr Aesthet Surg. 2024;94:223–228. doi:10.1016/j.bjps.2024.05.004

29. Knoz M, Wang YM, Luo SD, et al. Contraction-type vs noncontraction-type lymphatic vessels in LVA — propensity-matched cohort. Int J Surg. 2024;110(4):1913–1918. doi:10.1097/JS9.0000000000001106

30. Tsai PL, Wu SC, Lin WC, et al. Determining factors of lymphovascular characteristics and anastomotic configuration in supermicro LVA. Int J Surg. 2020;81:39–46. doi:10.1016/j.ijsu.2020.07.011

31. AlJindan FK, Lin CY, Cheng MH. Side-to-end vs end-to-end LVA for early-grade extremity lymphedema. Plast Reconstr Surg. 2019;144(2):486–496. doi:10.1097/PRS.0000000000005870

32. Kwon JG, Jeong S, Pak CJ, Suh HP, Hong JP. Side-to-end vs end-to-end LVA for secondary lower-limb lymphedema. Plast Reconstr Surg. 2022;150(5):1138–1148. doi:10.1097/PRS.0000000000009647

33. Yamamoto T, Yoshimatsu H, Yamamoto N, et al. SEATTLE — side-to-end LVA through temporary lymphatic expansion. PLoS One. 2013;8(3):e59523. doi:10.1371/journal.pone.0059523

34. Yamamoto T, Yoshimatsu H, Narushima M, et al. Modified side-to-end LVA. Microsurgery. 2013;33(2):130–133. doi:10.1002/micr.22040

35. Zeltzer A, Nistor A, Adriaenssens N, et al. Outcomes of LVA and VLNT in the combined surgical treatment of lymphedema — prospective cohort. Plast Reconstr Surg. 2025. doi:10.1097/PRS.0000000000012326

36. Brown S, Shen Y, Klimitz FJ, et al. LVB for secondary lymphedema — meta-analysis of prospective outcomes. Breast Cancer Res Treat. 2025;215(1):42. doi:10.1007/s10549-025-07867-4

37. Hahn BA, Kleeven A, Richir MC, et al. Objectifying clinical outcomes after LVA and VLNT for extremity lymphedema. Microsurgery. 2025;45(3):e70050. doi:10.1002/micr.70050

38. Thomas M, Pike C, Humphreys I, Bragg T, Ghattaura A. Impact and outcomes after LVA for 150 cases of lymphoedema followed up over 24 mo. J Plast Reconstr Aesthet Surg. 2023;85:104–113. doi:10.1016/j.bjps.2023.06.068

39. Nicholas Jungbauer W, Solomon S, Verhey EM, et al. LVA and VLNT reduce long-term cellulitis events — SR / meta-analysis. Ann Plast Surg. 2025;95(5):522–530. doi:10.1097/SAP.0000000000004508

40. Qiu SS, Pruimboom T, Cornelissen AJM, et al. Outcomes after LVA for 100 cases of lymphedema — 24-mo follow-up. Breast Cancer Res Treat. 2020;184(1):173–183. doi:10.1007/s10549-020-05839-4

41. Garza RM, Beederman M, Chang DW. Physical and functional outcomes of simultaneous VLNT and LVB in lymphedema. Plast Reconstr Surg. 2022;150(1):169–180. doi:10.1097/PRS.0000000000009247

42. Humphreys I, Thomas M, Pike C, et al. Cost-effectiveness analysis of LVA in reducing cellulitis recurrence in 150 lymphoedema cases over 24 mo. J Plast Reconstr Aesthet Surg. 2025;106:42–49. doi:10.1016/j.bjps.2025.04.032

43. Wolfs JAGN, de Joode LGEH, van der Hulst RRWJ, Qiu SS. Correlation between patency and clinical improvement after LVA in BCRL — 12-mo follow-up. Breast Cancer Res Treat. 2020;179(1):131–138. doi:10.1007/s10549-019-05450-2

44. Winters H, Tielemans HJP, Verhulst AC, et al. Long-term patency of LVA in BCRL. Ann Plast Surg. 2019;82(2):196–200. doi:10.1097/SAP.0000000000001674

45. Maegawa J, Yabuki Y, Tomoeda H, Hosono M, Yasumura K. Outcomes of LVA side-to-end anastomosis in peripheral lymphedema. J Vasc Surg. 2012;55(3):753–760. doi:10.1016/j.jvs.2011.08.062

46. Boccardo F, Santori G, Villa G, Accogli S, Dessalvi S. Long-term patency of multiple LVAs in cancer-related lymphedema. Microsurgery. 2022;42(7):668–676. doi:10.1002/micr.30944

47. Kang D. Hemodynamic challenges of lower-extremity LVA — critical reappraisal. J Clin Med. 2026;15(4):1594. doi:10.3390/jcm15041594

48. Beederman M, Garza RM, Agarwal S, Chang DW. Outcomes for physiologic microsurgical treatment of secondary extremity lymphedema. Ann Surg. 2022;276(4):e255–e263. doi:10.1097/SLA.0000000000004457

49. Seidenstuecker K, Müller VA, Halbeisen FS, et al. Long-term comparative effectiveness of microsurgical treatments for lower-limb lymphedema — LVA vs VLNT. J Plast Reconstr Aesthet Surg. 2026;117:26–32. doi:10.1016/j.bjps.2026.03.048

50. Boccardo F, Santori G, Fedre B, et al. LYMPHA technique to prevent arm lymphedema after breast cancer — 15-yr follow-up. Ann Surg Oncol. 2026. doi:10.1245/s10434-026-19526-z

51. Hinson C, Sink M, Henn D, et al. Preventing secondary lymphedema — SR / meta-analysis on efficacy of immediate LVA. J Surg Oncol. 2025;132(4):717–726. doi:10.1002/jso.70046

52. Ozmen T, Lazaro M, Zhou Y, Vinyard A, Avisar E. Evaluation of S-LYMPHA for prevention of clinical BCRL after axillary LND. Ann Surg. 2019;270(6):1156–1160. doi:10.1097/SLA.0000000000002827

53. Cho MJ, Senger JL, Park KU, et al. Preventing BCRL — 9-year single-center pLVB analysis. Ann Surg Oncol. 2025;32(3):2007–2015. doi:10.1245/s10434-024-16640-8

56. Sanka SA, Chryssofos S, Anolik RA, Sacks JM. Advances in surgical management of chronic lymphedema. Med Oncol. 2025;42(2):44. doi:10.1007/s12032-024-02576-2

57. Abdelfattah U, Elbanoby T, Hamza F, et al. Treatment of advanced male genital lymphedema with a complete functional lymphatic-system pedicled transfer. Urology. 2023;175:190–195. doi:10.1016/j.urology.2023.02.006

58. Imai H, Yoshida S, Mese T, et al. Correlation between lymphatic-surgery outcome and lymphatic image-staging or clinical severity in lymphedema. J Clin Med. 2022;11(17):4979. doi:10.3390/jcm11174979